Velliyur Viswesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Velliyur Viswesh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daekyu Sun
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
2 shared publications Guogen Shan
Department of Biostatistics, University of Florida, Gainesville, FL, USA
2 shared publicationsKent Gates
Departments of Chemistry and Biochemistry, University of Missouri, Columbia, MO 65211
2 shared publicationsAllison M. Hays
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721
1 shared publicationAna L. Hincapie
Division of Pharmacy Practice and Administrative Sciences, University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH
1 shared publicationBruce Kaplan
Division of Nephrology and Hypertension, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
1 shared publication
Latest Publications
- 5 May 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (12) , 1299-1307
Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
Background: Multidrug-resistant Acinetobacter baumannii remains challenging to treat. Although eravacycline has in vitro activity against this pathogen, there are no studies evaluating outcomes. Objective: To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR) A. baumannii pneumonia. Methods: This was a retrospective study of adults hospitalized for pneumonia with DTR A. baumannii. Patients receiving eravacycline were compared with those receiving best previously available therapy. The primary outcome was 30-day in-hospital mortality. Secondary outcomes included clinical cure at Day 14, hospital and intensive care unit (ICU) length of stay, microbiologic cure, and readmission within 90 days with a positive A. baumannii respiratory culture. Results: Ninety-three patients were included, with 27 receiving eravacycline. Eravacycline was associated with higher 30-day mortality (33% vs 15%; P = 0.048), lower microbiologic cure (17% vs 59%; P = 0.004), and longer durations of mechanical ventilation (10.5 vs 6.5 days; P = 0.016). At baseline, eravacycline patients had more A. baumannii bacteremia and coinfection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Among bacteremic patients, all 4 receiving eravacycline died by Day 30 and both patients receiving best previously available therapy survived. Upon exclusion of patients with bacteremia and SARS-CoV-2, there were no differences between the groups across any outcomes. Conclusions: Eravacycline-based combination therapy had similar outcomes to best previously available combination therapy for adults with DTR A. baumannii pneumonia. However, eravacycline should be used with caution in the setting of bacteremia as outcomes were poor in this population.
- 5 May 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (12) , 1299-1307
Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
Background: Multidrug-resistant Acinetobacter baumannii remains challenging to treat. Although eravacycline has in vitro activity against this pathogen, there are no studies evaluating outcomes. Objective: To assess the efficacy of eravacycline compared with best previously available therapy in adults with difficult-to-treat resistant (DTR) A. baumannii pneumonia. Methods: This was a retrospective study of adults hospitalized for pneumonia with DTR A. baumannii. Patients receiving eravacycline were compared with those receiving best previously available therapy. The primary outcome was 30-day in-hospital mortality. Secondary outcomes included clinical cure at Day 14, hospital and intensive care unit (ICU) length of stay, microbiologic cure, and readmission within 90 days with a positive A. baumannii respiratory culture. Results: Ninety-three patients were included, with 27 receiving eravacycline. Eravacycline was associated with higher 30-day mortality (33% vs 15%; P = 0.048), lower microbiologic cure (17% vs 59%; P = 0.004), and longer durations of mechanical ventilation (10.5 vs 6.5 days; P = 0.016). At baseline, eravacycline patients had more A. baumannii bacteremia and coinfection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Among bacteremic patients, all 4 receiving eravacycline died by Day 30 and both patients receiving best previously available therapy survived. Upon exclusion of patients with bacteremia and SARS-CoV-2, there were no differences between the groups across any outcomes. Conclusions: Eravacycline-based combination therapy had similar outcomes to best previously available combination therapy for adults with DTR A. baumannii pneumonia. However, eravacycline should be used with caution in the setting of bacteremia as outcomes were poor in this population.
- 10 October 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (11) , 1089-1098
Evaluation of Guideline Recommendations for Dual Antipseudomonal Therapy in Hospitalized Adults with Pneumonia Using Combination Antibiograms
Background: Guidelines for pneumonia recommend empiric dual antipseudomonal therapy in patients with specific risk factors. However, there is lack of consensus on when to use dual antipseudomonal therapy as the recommendations are rated as weak, based on low‐quality evidence.Objectives: The objectives of this study were to develop combination antibiograms to assess the susceptibility of Pseudomonas aeruginosa (P. aeruginosa) in respiratory cultures to combinations of empiric antibiotics and to use combination antibiograms to delineate the impact of specific risk factors for which guidelines recommend dual antipseudomonal therapy.Methods: A retrospective cohort study was conducted of adults hospitalized with pneumonia with positive respiratory cultures for P. aeruginosa between September 2014 and September 2018. Data collected included demographics, antimicrobial susceptibility results, and risk factors for which guidelines recommend dual antipseudomonal therapy. Combination antibiograms were developed and logistic regression was performed to identify risk factors for nonsusceptibility to beta‐lactams.Results: Eight hundred nineteen patients were included and 72% received antibiotics. Beta‐lactam susceptibility ranged from 58% to 69% and addition of a fluoroquinolone or aminoglycoside resulted in statistically significant increases in susceptibility. However, only addition of tobramycin or amikacin provided susceptibility rates approaching or exceeding 90% stratified by pneumonia type and risk factors. Presence of guideline‐based risk factors generally resulted in reduced susceptibility rates. Logistic regression identified three risk factors associated with nonsusceptibility to beta‐lactams: intravenous antibiotics in the previous 90 days, nursing home residence, and mechanical ventilation at onset. The cumulative presence of each additional risk factor affected beta‐lactam susceptibility rates, which were 93% in the absence of any risk factors and 39% when all three risk factors co‐existed.Conclusions: Risk factors necessitating dual antipseudomonal therapy for pneumonia should be locally validated. When dual antipseudomonal therapy is indicated, tobramycin or amikacin have the best likelihood of providing adequate in vitro activity.
- 10 October 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (11) , 1089-1098
Evaluation of Guideline Recommendations for Dual Antipseudomonal Therapy in Hospitalized Adults with Pneumonia Using Combination Antibiograms
Background: Guidelines for pneumonia recommend empiric dual antipseudomonal therapy in patients with specific risk factors. However, there is lack of consensus on when to use dual antipseudomonal therapy as the recommendations are rated as weak, based on low‐quality evidence.Objectives: The objectives of this study were to develop combination antibiograms to assess the susceptibility of Pseudomonas aeruginosa (P. aeruginosa) in respiratory cultures to combinations of empiric antibiotics and to use combination antibiograms to delineate the impact of specific risk factors for which guidelines recommend dual antipseudomonal therapy.Methods: A retrospective cohort study was conducted of adults hospitalized with pneumonia with positive respiratory cultures for P. aeruginosa between September 2014 and September 2018. Data collected included demographics, antimicrobial susceptibility results, and risk factors for which guidelines recommend dual antipseudomonal therapy. Combination antibiograms were developed and logistic regression was performed to identify risk factors for nonsusceptibility to beta‐lactams.Results: Eight hundred nineteen patients were included and 72% received antibiotics. Beta‐lactam susceptibility ranged from 58% to 69% and addition of a fluoroquinolone or aminoglycoside resulted in statistically significant increases in susceptibility. However, only addition of tobramycin or amikacin provided susceptibility rates approaching or exceeding 90% stratified by pneumonia type and risk factors. Presence of guideline‐based risk factors generally resulted in reduced susceptibility rates. Logistic regression identified three risk factors associated with nonsusceptibility to beta‐lactams: intravenous antibiotics in the previous 90 days, nursing home residence, and mechanical ventilation at onset. The cumulative presence of each additional risk factor affected beta‐lactam susceptibility rates, which were 93% in the absence of any risk factors and 39% when all three risk factors co‐existed.Conclusions: Risk factors necessitating dual antipseudomonal therapy for pneumonia should be locally validated. When dual antipseudomonal therapy is indicated, tobramycin or amikacin have the best likelihood of providing adequate in vitro activity.
- 1 December 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (12) , 1543-1549
Motivators, barriers, and strategies to improve response rate to student evaluation of teaching
- 1 December 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (12) , 1543-1549
Motivators, barriers, and strategies to improve response rate to student evaluation of teaching
- 1 May 2018
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 82 (4) , 6278
Evaluation of a Modified Debate Exercise Adapted to the Pedagogy of Team-Based Learning
Objective. To assess the impact of a debate exercise on self-reported evidence of student learning in literature evaluation, evidence-based decision making, and oral presentation.Methods. Third-yea...
- 1 May 2018
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 82 (4) , 6278
Evaluation of a Modified Debate Exercise Adapted to the Pedagogy of Team-Based Learning
Objective. To assess the impact of a debate exercise on self-reported evidence of student learning in literature evaluation, evidence-based decision making, and oral presentation.Methods. Third-yea...
- 1 April 2017
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 74 (7) , 474-482
Development of a bedside scoring system for predicting a first recurrence ofClostridium difficile–associated diarrhea
Purpose A scoring system for identifying patients at high or low risk for recurrent Clostridium difficile–associated diarrhea (CDAD) is described. Methods A retrospective cohort study was performed using data on adults with CDAD admitted to a 3-hospital system from 2009 to 2014. The primary endpoint was the rate of recurrent CDAD within 60 days of clinical cure of CDAD. Risk factors for CDAD recurrence were identified, and a risk prediction tool was developed using multivariate logistic regression. Results The CDAD cure rate in the study cohort (n = 340) was 92.3%; the 60-day recurrence rate was 16.9%. Five factors were significantly associated with high recurrence risk: presence of CDAD at admission, body temperature of >37.8 °C at admission, leukocytosis, nosocomial CDAD, and abdominal distention on CDAD presentation. From that information a risk prediction tool, the CDAD “recurrence score,” was developed (1 point is assigned for each factor present, for a maximum score of 5). Validation testing of the recurrence score indicated an area under the receiver operating characteristic curve of 0.72 (95% confidence interval, 0.65–0.80). A score of ≥2 had a negative predictive value of 91%, while a score of ≥4 had a positive predictive value of 70%. Conclusion If externally validated in future studies, a tool for predicting the risk of recurrent CDAD using data readily available at the time of presentation could allow clinicians to identify patients at high risk for recurrence, address modifiable risk factors, and select tailored treatments to improve patient outcomes.
- 1 April 2017
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 74 (7) , 474-482
Development of a bedside scoring system for predicting a first recurrence ofClostridium difficile–associated diarrhea
Purpose A scoring system for identifying patients at high or low risk for recurrent Clostridium difficile–associated diarrhea (CDAD) is described. Methods A retrospective cohort study was performed using data on adults with CDAD admitted to a 3-hospital system from 2009 to 2014. The primary endpoint was the rate of recurrent CDAD within 60 days of clinical cure of CDAD. Risk factors for CDAD recurrence were identified, and a risk prediction tool was developed using multivariate logistic regression. Results The CDAD cure rate in the study cohort (n = 340) was 92.3%; the 60-day recurrence rate was 16.9%. Five factors were significantly associated with high recurrence risk: presence of CDAD at admission, body temperature of >37.8 °C at admission, leukocytosis, nosocomial CDAD, and abdominal distention on CDAD presentation. From that information a risk prediction tool, the CDAD “recurrence score,” was developed (1 point is assigned for each factor present, for a maximum score of 5). Validation testing of the recurrence score indicated an area under the receiver operating characteristic curve of 0.72 (95% confidence interval, 0.65–0.80). A score of ≥2 had a negative predictive value of 91%, while a score of ≥4 had a positive predictive value of 70%. Conclusion If externally validated in future studies, a tool for predicting the risk of recurrent CDAD using data readily available at the time of presentation could allow clinicians to identify patients at high risk for recurrence, address modifiable risk factors, and select tailored treatments to improve patient outcomes.
- 1 July 2015
- Published by Elsevier in Transplantation Reviews
- Vol. 29 (3) , 175-180
The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review
- 1 July 2015
- Published by Elsevier in Transplantation Reviews
- Vol. 29 (3) , 175-180
The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review
- 1 September 2014
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 22 (5) , 283-287
Efficacy of an Alternative Dosing Strategy of Meropenem in the Treatment of High-Risk Febrile Neutropenia in Adult Subjects
Background High-risk febrile neutropenia (FN), an oncologic emergency common in patients receiving myelosuppressive chemotherapy, requires prompt initiation of broad-spectrum antibacterials with current guidelines recommending meropenem 1 g intravenously (IV) every 8 hours as first-line treatment. However, an alternative dosage of meropenem, 500 mg IV every 6 hours, has been shown to attain a similar percentage of time above the minimum inhibitory concentration (%T > minimum inhibitory concentration) with a lower daily dose and associated drug cost in nonneutropenic subjects. Methods A retrospective study was conducted in adult subjects with FN who received the alternative dosage of meropenem during a 31-month period (February 2009 to August 2011). The primary end point was time to defervescence. Secondary end points included the need for additional gram-negative antibacterials, duration of meropenem treatment, and in-hospital mortality. Results A total of 449 subjects were screened with 74 meeting inclusion criteria. Median time to defervescence was 2 days. Additional gram-negative antibacterials were used in 6 subjects (8.1%), and in-hospital mortality occurred in 5 subjects (6.8%). Median duration of meropenem treatment was 5 days. There was a significant correlation toward a longer time to defervescence with longer durations of neutropenia (r = 0.272, P = 0.034). Conclusions The alternative meropenem dosage regimen of 500 mg IV every 6 hours therefore yields similar outcomes as previously reported with conventional doses of 1 g IV every 8 hours in adults with FN, with potential cost savings due to a decreased daily meropenem dose.
- 1 September 2014
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 22 (5) , 283-287
Efficacy of an Alternative Dosing Strategy of Meropenem in the Treatment of High-Risk Febrile Neutropenia in Adult Subjects
Background High-risk febrile neutropenia (FN), an oncologic emergency common in patients receiving myelosuppressive chemotherapy, requires prompt initiation of broad-spectrum antibacterials with current guidelines recommending meropenem 1 g intravenously (IV) every 8 hours as first-line treatment. However, an alternative dosage of meropenem, 500 mg IV every 6 hours, has been shown to attain a similar percentage of time above the minimum inhibitory concentration (%T > minimum inhibitory concentration) with a lower daily dose and associated drug cost in nonneutropenic subjects. Methods A retrospective study was conducted in adult subjects with FN who received the alternative dosage of meropenem during a 31-month period (February 2009 to August 2011). The primary end point was time to defervescence. Secondary end points included the need for additional gram-negative antibacterials, duration of meropenem treatment, and in-hospital mortality. Results A total of 449 subjects were screened with 74 meeting inclusion criteria. Median time to defervescence was 2 days. Additional gram-negative antibacterials were used in 6 subjects (8.1%), and in-hospital mortality occurred in 5 subjects (6.8%). Median duration of meropenem treatment was 5 days. There was a significant correlation toward a longer time to defervescence with longer durations of neutropenia (r = 0.272, P = 0.034). Conclusions The alternative meropenem dosage regimen of 500 mg IV every 6 hours therefore yields similar outcomes as previously reported with conventional doses of 1 g IV every 8 hours in adults with FN, with potential cost savings due to a decreased daily meropenem dose.
- 1 December 2013
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 41 (12) , e487-e488
Inclusion and Recommendation of (1→3)-β-D-Glucan Testing in the International Guidelines for Management of Severe Sepsis and Septic Shock
- 1 December 2013
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 41 (12) , e487-e488
Inclusion and Recommendation of (1→3)-β-D-Glucan Testing in the International Guidelines for Management of Severe Sepsis and Septic Shock
- 4 September 2012
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 26 (3) , 254-256
Unpredictable Absorption of Oral Opioid Medications in a Quadriplegic Patient With Chronic Enterocutaneous Fistulas
Although there is an abundance of literature on the acute management of enterocutaneous fistulas, there is a paucity of data on the chronic management of enterocutaneous fistulas. Their impact on oral pharmacotherapy, including their effect on the bioavailability of oral medications, is poorly understood. This case describes a 23-year-old quadriplegic male with a complex history of multiple abdominal surgeries presented with three persistent enterocutaneous fistulas. Diazepam and furosemide were among the patient's oral medications and had sufficient bioavailability to show efficacy on anxiety and pedal edema, respectively. Conversely, oral oxycodone and methadone were ineffective in controlling chronic pain despite high doses and aggressive titration. Due to inadequate pain control, the patient supplemented opioid medications with high doses of lorazepam and diazepam to augment psychological comfort. A trial of subcutaneous morphine successfully produced immediate analgesia, causing a marked reduction in benzodiazepine use. Enterocutaneous fistulas may reduce the bioavailability of oral medications to various degrees depending upon the medication. Further research is needed to elucidate the effect chronic enterocutaneous fistulas have on the bioavailability of oral medications. It is therefore important for clinicians to question the bioavailability of medications in the setting of enterocutaneous fistulas and poor clinical response.
- 4 September 2012
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 26 (3) , 254-256
Unpredictable Absorption of Oral Opioid Medications in a Quadriplegic Patient With Chronic Enterocutaneous Fistulas
Although there is an abundance of literature on the acute management of enterocutaneous fistulas, there is a paucity of data on the chronic management of enterocutaneous fistulas. Their impact on oral pharmacotherapy, including their effect on the bioavailability of oral medications, is poorly understood. This case describes a 23-year-old quadriplegic male with a complex history of multiple abdominal surgeries presented with three persistent enterocutaneous fistulas. Diazepam and furosemide were among the patient's oral medications and had sufficient bioavailability to show efficacy on anxiety and pedal edema, respectively. Conversely, oral oxycodone and methadone were ineffective in controlling chronic pain despite high doses and aggressive titration. Due to inadequate pain control, the patient supplemented opioid medications with high doses of lorazepam and diazepam to augment psychological comfort. A trial of subcutaneous morphine successfully produced immediate analgesia, causing a marked reduction in benzodiazepine use. Enterocutaneous fistulas may reduce the bioavailability of oral medications to various degrees depending upon the medication. Further research is needed to elucidate the effect chronic enterocutaneous fistulas have on the bioavailability of oral medications. It is therefore important for clinicians to question the bioavailability of medications in the setting of enterocutaneous fistulas and poor clinical response.